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ultrasound‑guided drainage of pancreatic fluid collections
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Douglas G. Adler, Linda Jo Taylor, Raza Hasan1, Ali A. Siddiqui1
Department of Internal Medicine, Division of Gastroenterology, University of Utah Hospital, Salt Lake City, UT, 1Division
of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA, USA

ABSTRACT
Objectives: To report the safety and clinical efficacy with the novel lumen‑apposing metal stent (LAMS) with an electrocautery
enhanced delivery system for the drainage of pancreatic fluid collections (PFCs). Methods: This was a retrospective
analysis of all consecutive patients with PFCs who underwent endoscopic ultrasound (EUS)‑guided drainage using the
LAMS with an electrocautery enhanced delivery system in 2 US centers. Results: Thirteen patients with PFCs (69% with
walled‑off necrosis [WON]) underwent drainage using the study device. Successful stent placement was accomplished
in all patients. Direct endoscopic necrosectomy was carried out in all nine patients with WON complete resolution of the
PFC was obtained in all 13 cases, with no recurrence during follow‑up. There was one procedure‑related adverse event.
In one patient, the LAMS was dislodged immediately after deployment, falling into the stomach where it was removed.
A second electrocautery enhanced LAMS was placed in this patient immediately afterward. Conclusions: EUS‑guided
drainage using the LAMS with the electrocautery‑enhanced delivery system is a safe, easily performed, and a highly
effective for the drainage of PFCs.
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INTRODUCTION
In the current era, endoscopists are frequently
called on to diagnose and more importantly, treat
pancreatic fluid collections (PFCs). PFCs are known to
develop as a consequence of pancreatic ductal injury
following episodes of acute pancreatitis and can be
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seen in patients with chronic pancreatitis, iatrogenic
causes (i.e., surgery), trauma, or in patients with the
so‑called disconnected duct syndrome. [1‑3] PFCs can
be delineated as either pancreatic pseudocysts (PPs)
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or walled‑off necrosis (WON), with the former being
fluid collections in the peripancreatic tissues that are
surrounded by a well‑defined wall and contain little
to no solid material, the latter consist of necrotic
tissue (often admixed with fluid), contained within a
wall of reactive tissue. PFCs often produce symptoms
including pain, gastric outlet obstruction, biliary
obstruction, and can sometimes become infected.[4]
PFCs can be managed by a variety of approaches,
including endoscopic, surgical, and percutaneous
drainage; some patients require multiple modalities
to treat these lesions.[5‑7] The surgical approach is the
most well‑established means of draining PFCs can be
performed laparoscopically but is invasive and carries a
relatively high mortality and morbidity.[8] Percutaneous
drainage of PFCs carries several risks including the
risk of fistula formation, cyst recurrence, and infection
although this approach is minimally invasive when
compared to other treatment options.
Endoscopic drainage and debridement of PFCs,
once rare, are now perfor med at many centers
and have shown a high degree of both efficacy
and safety. [9] The procedure is usually endoscopic
ultrasound (EUS)‑based. EUS‑guided drainage has been
shown to have a high success rate (87%–97%) with a
low complication (6%–34%) and mortality (0%–1%)
rate.[10,11]
Recently, lumen‑apposing fully covered self‑expanding
lumen‑apposing metal stent (LAMS) has become
commercially available and has been demonstrated to
be both safe and effective for endoscopic transmural
drainage of PPs and WONs.[12‑14]
Our group recently reported results of a large
multicenter study using the first‑generation version of
one of these devices (Axios Stent, Boston Scientific,
Natick MA).[15] This study included 82 patients with
PP or WON. The mean size of the PFC was 11.8 cm.
LAMSs were successfully placed in 80 patients (97.5%).
Endoscopic debridement with the LAMS in WON was
performed in 54 patients. The patency of the stent was
maintained in 98.7% of the patients (77/78). Successful
endoscopic therapy using the LAMS was successful
in 12 of 12 patients (100%) with PP compared with
60 of 68 patients (88.2%) with WON. All stents were
endoscopically removed from all patients after peri‑PFC
resolution. There was 1 PFC recurrence during the
3‑month median follow‑up period. Overall, adverse
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events were uncommon and clinical and technical
success was high.
This study used the so‑called “cold” version of this
stent. This device, while highly effective, still requires
the endoscopists to access the PFC with an EUS FNA
needle, place a guidewire into the cyst, and dilate the
cystgastrostomy tract before the LAMS can be placed.
The “hot” version of this device allows direct access
to the PFC without the need for these steps through
a diathermic tip of the LAMS delivery catheter, thus
simplifying the procedure considerably. We report in
this study our initial multicenter experience with the
“hot” version of this stent, so named for a diathermic
tip on the stent deployment catheter used to create the
cystenterostomy. The use of a diathermic tip speeds
the procedure and potentially eliminates several steps
from the stent deployment procedure, saving both time,
equipment, and costs.
METHODS
We performed a multi‑center, retrospective study
conducted at 2 tertiary care centers. The study was
approved by the Institutional Review Boards in both
centers. The study concept, hypothesis, and design
were investigator initiated and no ﬁnancial support was
received.
The endoscopy database at the University of Utah
Hospitals and Clinics and Thomas Jefferson University
Hospital was queried for all patients who had
undergone EUS‑guided drainage of PFCs (i.e., PP
and WON) using the diathermic‑tip LAMS between
February 2012 and June 2014. Only patients with a
3‑month or greater follow‑up were included in the
study.
PFCs were characterized by magnetic resonance imaging
or computed tomography (CT) in concordance with
EUS findings. WONs included in this study consisted
of a mature, encapsulated collection of pancreatic,
and/or peripancreatic necrotic tissue contained
within an enhancing wall of reactive tissue. PPs were
defined as an encapsulated collection of fluid with
a well‑defined inflammatory wall usually outside the
pancreas with minimal or no necrosis (as per the
revised Atlanta Classification).[1]
The indications for drainage of PFCs included (1) pain
felt to be secondary to the PFC, (2) gastric outlet or
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biliary obstruction secondary to compression by the
PFC, (3) ongoing systemic illness, anorexia, and weight
loss, (4) rapidly enlarging PFCs, and/or (5) infected
PFCs.[16] Some patients had more than one inclusion
criteria. Data recorded from outpatient and hospital
records to collect procedural details and overall clinical
course of the patient.

Description of the lumen‑apposing metal stent

The LAMS (Hot AXIOS™; Boston Scientific, Natick
MA) is a saddle‑shaped nitinol, braided flexible
fully‑covered stent. The stent has bilateral double‑walled
anchoring flanges designed to hold the stomach or
duodenal wall in direct apposition to the inner wall of
the PFC. The stent is available in 2 different lumen
diameters (10 mm and 15 mm) and is 10 mm long.

Techniques

All patients underwent procedures by endoscopists
with > 5 years of endosonography practice (DGA
and AAS). PFC drainage was performed using the
therapeutic linear array echoendoscope (Olympus;
Center Valley, PA, USA). All procedures were
performed under general anesthesia. Patients were
given broad‑spectrum antibiotics during and after the
procedure to decrease the risk of secondary infection.
Transgastric and transduodenal routes were evaluated in
all patients before creation of a cystenterostomy. EUS
imaging was used to determine the optimal puncture
site of the cyst [Figure 1]. Color Doppler was used to
exclude interposed vessels at the puncture site.

a cystenterostomy. The stent delivery system was
pressed against the gastric or duodenal lumen while
electrocautery what delivered, essentially cutting and
coagulating the cystenterostomy tract simultaneously.
Cautery settings were as follows: auto cut, effect
4, 100 Watts on an ERBE ICC 200 electrocautery
generator as recommended by the manufacturer of the
LAMS (ERBE USA, Marietta Georgia). These settings
were used for all procedures and were not adjusted for
either transgastric or transduodenal placement.
The selection of stent diameter (10 mm or 15 mm)
was at the discretion of the endoscopists based
on the size and contents of the cyst but was not
dependent on the route of placement of the LAMS.
The distal flange of the stent was deployed under EUS
guidance followed by positioning of this flange against
the PFC wall. Deployment of the proximal flange
was then performed under endoscopic and/or EUS
guidance [Figures 2 and 3].

Under EUS guidance, the stent delivery system was
advanced until it was in contact with the gastric or
duodenal wall in optimal position for creation of

In patients with WON, endoscopic necrosectomy
sessions were performed using an upper endoscope
advanced through the LAMS at intervals selected by
the treating endoscopist, approximately every 3–14 days,
until complete debridement of the necrotic cavity
was performed as confirmed endoscopically and/or
by cross‑sectional imaging. Necrosectomy procedures
involved a mixture of PFC lavage with diluted hydrogen
peroxide mixed with sterile saline, blunt dissection, or
necrotic PFC contents using endoscopic catheters, and
capture and removal of necrotic tissue by a variety of
devices including endoscopic forceps, snares, baskets,
and retrieval net devices.

Figure 1. 7.5 MHz EUS image of a pancreatic fluid collection prior to
access and drainage

Figure 2. Endoscopic image of LAMS placed via electrocautery
enhanced system immediately after deployment
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manner, the remainder of the lesions was drained in a
transgastric manner.
All but one patient received a 15 mm diameter Axios
stent. Four patients had concomitant placement of a
plastic double‑pigtail stent through the Axios catheter to
reduce the risk of clogging in patients with an excessive
amount of solid debris and one patient underwent
placement of a nasocystic tube through the Axios stent
to allow the patient to perform saline lavage of the
stent at home as an outpatient.

Figure 3. Fluoroscopic image of LAMS after deployment

Complications including but not limited to perforation,
bleeding, hypotension, or respiratory distress were
recorded. The electronic medical records of hospital
admissions and ambulatory office visits were also
evaluated for any delayed complication (<30‑day after
procedure).
All patients were evaluated with periodic
contrast‑enhanced CT of the abdomen and pelvis
4–8 weeks after LAMS placement. Stent removal
was undertaken through the use of rat‑tooth
forceps through simple traction when complete
cyst decompression was achieved, i.e., the PFC had
completely resolved without any residual solid or fluid
contents remained. The cystogastrostomy site was left
to close secondarily and was not clipped or sutured
closed after LAMS removal.
RESULTS
Thirteen patients (5 male, 8 female) were included
in the study. The mean age of the patients was
58.3 years (range 32–92). The etiology of the patient’s
pancreatitis was as follows: gallstones n = 6, alcohol
n = 5, hypertriglyceridemia n = 1, idiopathic n = 1.
The mean size of the PFC was 138 mm
(range 60–159 mm). Four lesions (31%) were felt to
be pseudocysts, 9 lesions (69%) were felt to be WONs
based on EUS and cross‑sectional imaging. Two lesions
were located in the region of the pancreatic head,
8 lesions were located in the region of the pancreatic
body, and three lesions were located in the region
of the pancreatic tail. The PFCs in the region of
the pancreatic head were drained in a transduodenal
392

All procedures were technically successful. The mean
procedure time was 15 min (range 8–32 min). There
was one procedure‑related adverse event. In one
patient, the Axios stent was dislodged immediately
after deployment, falling into the stomach where it
was removed. A second hot Axios stent was placed in
this patient immediately afterward without any adverse
event. Of note, there was no bleeding at any of the
cystenterostomy sites.
All patients with WON underwent endoscopic
necrosectomy with a mean of 3 sessions per
patient (range 1–6 sessions). All Axios stents were
removed without difficulty. Mean stent indwell time
was 2 months (range 2–4 months), and patients had
recurrence of their PFCs in a mean duration of
follow‑up of 2.5 months (range 2–6 months).
DISCUSSION
Traditional cystenterostomy for PFC drainage involves
several steps, including accessing the PFC with
a EUS FNA needle (typically 19‑gauge) to allow
guidewire advancement and looping, dilation of the
cystenterostomy with a dilation balloon, and then the
placement of one or more plastic or metal stents across
the cystenterostomy. Although simple in concept, the
procedure can be technically very demanding with
limited endoscopic visualization, easy loss of access
to the PFC at any step of the procedure, and risks
of bleeding and perforation from the creation of the
cystenterostomy.
The diathermic‑tipped device used in this series
eliminates the need for the endoscopist to use an
EUS FNA needle to puncture the PFC as well as
eliminates the need for a guidewire at all although one
can be inserted through the stent delivery catheter if
desired. Furthermore, as the diathermic tip creates
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an initial cystgastrostomy identical in diameter to the
stent delivery catheter, no dilation is needed before
stent deployment. The stent gradually dilates the
cystenterostomy after deployment, ultimately reaching
its final inner diameter.
This device potentially eliminates the need for three
other devices at the time of deployment, potentially
resulting in significant cost savings although the “hot”
version of the device is more expensive than the “cold”
version. In addition, the elimination of these other
steps in the creation of the cystenterostomy reduces
time.
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CONCLUSION
The electrocautery enhanced LAMS device proved safe,
effective, and efficient for the access and drainage of
pancreatic fluid collections.

Financial support and sponsorship

11.
12.

13.

This study was funded entirely by existing intramural
funds and salary support in the respective institutions.
14.

Conflicts of interest

There are no conflicts of interest.
15.

REFERENCES
1.

2.

Banks PA, Bollen TL, Dervenis C, et al. Classification of acute
pancreatitis‑2012: Revision of the Atlanta classification and definitions by
international consensus. Gut 2013;62:102‑11.
Baillie J. Pancreatic pseudocysts (Part I). Gastrointest Endosc 2004;59:873‑9.

16.

Brun A, Agarwal N, Pitchumoni CS. Fluid collections in and around the
pancreas in acute pancreatitis. J Clin Gastroenterol 2011;45:614‑25.
Yeo CJ, Bastidas JA, Lynch‑Nyhan A, et al. The natural history of
pancreatic pseudocysts documented by computed tomography. Surg
Gynecol Obstet 1990;170:411‑7.
Tsiotos GG, Sarr MG. Management of fluid collections and necrosis in
acute pancreatitis. Curr Gastroenterol Rep 1999;1:139‑44.
Baron TH, Harewood GC, Morgan DE, et al. Outcome differences after
endoscopic drainage of pancreatic necrosis, acute pancreatic pseudocysts,
and chronic pancreatic pseudocysts. Gastrointest Endosc 2002;56:7‑17.
Nealon WH, Walser E. Main pancreatic ductal anatomy can direct
choice of modality for treating pancreatic pseudocysts (surgery versus
percutaneous drainage). Ann Surg 2002;235:751‑8.
Vitas GJ, Sarr MG. Selected management of pancreatic pseudocysts:
Operative versus expectant management. Surgery 1992;111:123‑30.
Binmoeller KF, Seifert H, Walter A, Soehendra N. Transpapillary and
transmural drainage of pancreatic pseudocysts. Gastrointest Endosc
1995;42:219‑24.
Varadarajulu S, Bang JY, Phadnis MA, et al. Endoscopic transmural
drainage of peripancreatic fluid collections: Outcomes and predictors
of treatment success in 211 consecutive patients. J Gastrointest Surg
2011;15:2080‑8.
Varadarajulu S, Rana SS, Bhasin DK. Endoscopic therapy for pancreatic
duct leaks and disruptions. Gastrointest Endosc Clin N Am 2013;23:863‑92.
Binmoeller KF, Shah J. A novel lumen‑apposing stent for transluminal
drainage of nonadherent extraintestinal fluid collections. Endoscopy
2011;43:337‑42.
Shah RJ, Shah JN, Waxman I, et al. Safety and efficacy of endoscopic
ultrasound‑guided drainage of pancreatic fluid collections with
lumen‑apposing covered self‑expanding metal stents. Clin Gastroenterol
Hepatol 2015;13:747‑52.
Itoi T, Binmoeller KF, Shah J, et al. Clinical evaluation of a novel
lumen‑apposing metal stent for endosonography‑guided pancreatic
pseudocyst and gallbladder drainage (with videos). Gastrointest Endosc
2012;75:870‑6.
Siddiqui AA, Adler DG, Nieto J, et al. EUS‑guided drainage
of peripancreatic fluid collections and necrosis by using a novel
lumen‑apposing stent: A large retrospective, multicenter U.S.
experience (with videos). Gastrointest Endosc 2016;83:699‑707.
Jacobson BC, Baron TH, Adler DG, et al. ASGE guideline: The role
of endoscopy in the diagnosis and the management of cystic lesions
and inflammatory fluid collections of the pancreas. Gastrointest Endosc
2005;61:363‑70.

ENDOSCOPIC ULTRASOUND/ VOLUME 6 / ISSUE 6 | NOVEMBER-DECEMBER 2017

393

